Who are Nifedipine (Adalat, BAYA1040)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Levoamlodipine, Cleviprex, Sular, Dynacirc, Nimotop, Procardia.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nifedipine-adalat-baya1040.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Nifedipine (Adalat, BAYA1040) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nifedipine (Adalat, BAYA1040) (Nifedipine (Adalat, BAYA1040)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dihydropyridine calcium channel blocker. Area: Cardiovascular.

marketed Dihydropyridine calcium channel blocker L-type calcium channel Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Nifedipine (Adalat, BAYA1040) (Nifedipine (Adalat, BAYA1040)) — Bayer. Nifedipine blocks L-type calcium channels in vascular smooth muscle and cardiac tissue, reducing calcium influx and causing vasodilation and decreased cardiac contractility.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nifedipine (Adalat, BAYA1040) TARGET	Nifedipine (Adalat, BAYA1040)	Bayer	marketed	Dihydropyridine calcium channel blocker	L-type calcium channel
Levoamlodipine	LEVAMLODIPINE		marketed	levamlodipine	Voltage-gated L-type calcium channel	2019-01-01
Cleviprex	CLEVIDIPINE	Chiesi	marketed	Dihydropyridine Calcium Channel Blocker [EPC]	Voltage-dependent L-type calcium channel subunit alpha-1C	2008-01-01
Sular	NISOLDIPINE	Azurity	marketed	Dihydropyridine Calcium Channel Blocker [EPC]	Voltage-dependent L-type calcium channel subunit alpha-1C	1995-01-01
Dynacirc	ISRADIPINE	Smithkline Beecham	marketed	Dihydropyridine Calcium Channel Blocker [EPC]	Voltage-dependent L-type calcium channel subunit alpha-1D	1990-01-01
Nimotop	NIMODIPINE		marketed	Dihydropyridine Calcium Channel Blocker [EPC]	Voltage-dependent L-type calcium channel subunit alpha-1F	1988-01-01
Procardia	Nifedipine	Pfizer	marketed	Dihydropyridine Calcium Channel Blocker [EPC]	Voltage-dependent L-type calcium channel subunit alpha-1C	1981-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dihydropyridine calcium channel blocker class)

Bayer · 1 drug in this class
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · 1 drug in this class
Haseki Training and Research Hospital · 1 drug in this class
Jiangsu Simcere Pharmaceutical Co., Ltd. · 1 drug in this class
Korea University Guro Hospital · 1 drug in this class
Nanjing Yoko Biomedical Co., Ltd. · 1 drug in this class
Organon and Co · 1 drug in this class
Pfizer Inc. · 1 drug in this class
University Hospital Hradec Kralove · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nifedipine (Adalat, BAYA1040) — Competitive Intelligence Brief. https://druglandscape.com/ci/nifedipine-adalat-baya1040. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab